Vascular Disrupting Agents represent a potential new class of oncology drugs that disrupt established tumor vasculature, with promising clinical trial data emerging in NSCLC and other malignancies.
No takes yet. Share an insight, caveat, or question.
May expand NSCLC options beyond standard therapies; leaves open the need for phase 3 confirmation before clinical adoption.
Spear et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: